Valuation: Atossa Therapeutics, Inc.

Market Cap 19.76M 17.36M 16.14M 14.81M 27.83M 1.9B 28.26M 192M 74.89M 936M 74.19M 72.59M 3.24B P/E 2026 *
-0.53x
P/E 2027 * -0.66x
Enterprise Value 19.76M 17.36M 16.14M 14.81M 27.83M 1.9B 28.26M 192M 74.89M 936M 74.19M 72.59M 3.24B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.29%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Therapeutics, Inc.

1 day-4.77%
1 week-7.83%
Current month+18.91%
1 month+29.66%
3 months-59.74%
6 months-76.17%
Current year-74.07%
1 week 2.25
Extreme 2.25
2.6
1 month 1.89
Extreme 1.89
2.6
Current year 1.7
Extreme 1.7
10.95
1 year 1.7
Extreme 1.7
19.35
3 years 1.7
Extreme 1.7
34.65
5 years 1.7
Extreme 1.7
64.65
10 years 1.7
Extreme 1.7
780.3
Manager TitleAgeSince
Chief Executive Officer 75 31/03/2009
Director of Finance/CFO 50 13/10/2025
Chief Tech/Sci/R&D Officer - 30/09/2025
Director TitleAgeSince
Chairman 75 31/03/2009
Director/Board Member 64 31/03/2009
Director/Board Member 79 30/06/2011
Date Insider Type Main position Quantity % Market Cap.
12/05/26 Free

Director

10,000 0.1161%
12/05/26 Free

Director

10,000 0.1161%
12/05/26
Ensisheim Partners LLC
OtherCompany 0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-4.77%-7.83%-81.78%-85.43% 19.76M
+1.07%-3.49%-3.35%+10.44% 46.86B
+0.25%+1.65%+399.22%+634.87% 40.23B
-0.27%+4.45%+11.81%+65.64% 36.23B
+0.35%+0.87%+4.46%-10.16% 34.72B
+3.14%+1.02%+4.76%+40.92% 27.89B
-0.73%+11.84%+34.39%+134.36% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%-3.43%+9.03% 13.12B
-2.68%-2.49%-11.36%-33.61% 12.7B
Average -0.27%-0.04%+39.41%+85.12% 24.53B
Weighted average by Cap. +0.48%+0.91%+74.40%+136.25%

Financials

2026 *2027 *
Net sales - -
Net income -37.39M -32.84M -30.54M -28.03M -52.66M -3.6B -53.47M -363M -142M -1.77B -140M -137M -6.12B -39.31M -34.53M -32.11M -29.47M -55.36M -3.79B -56.22M -381M -149M -1.86B -148M -144M -6.44B
Net Debt - -
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
24/07/26 US$2.295 -4.77% 40,789
23/07/26 US$2.410 -0.82% 37,171
22/07/26 US$2.430 +1.25% 26,603
21/07/26 US$2.400 -3.61% 106,083
20/07/26 US$2.490 0.00% 117,295
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.295USD
Average target price
22.00USD
Spread / Average Target
+858.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATOS Stock